Navigation Links
AMDL Inc.'s Chairman & CEO Mr. Douglas MacLellan Featured on FOX Business News Wednesday, February 4, 2009

TUSTIN, Calif., Feb. 4 /PRNewswire-FirstCall/ -- AMDL, Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations China, announced today its Chairman and CEO Mr. Douglas MacLellan has appeared on Fox Business News today, Wednesday, February 4, 2009 at 6:40 a.m. ET (3:40 a.m. PT).

Mr. MacLellan was invited as a guest expert on Fox Business News to discuss the Chinese business environment specifically for pharmaceutical and healthcare companies, the Company's outlook for 2009 and its focus on growth in the emerging Chinese market, and how AMDL is leading the industry as one of the first US-based companies to enforce and implement Westernized business practices -- including SOX-compliant operating procedures and GAAP-certified accounting practices -- across its US and China operations.

According to Mr. MacLellan, "I'm extremely honored with an opportunity to address these important topics with Fox Business News. They are subjects investors inquire about most often when we communicate the AMDL story and topics that impact Wall Street's overall view and investing appetite for China-based pharmaceutical companies."

AMDL has successfully managed its US- and China-based operations despite the current economic downturn, delivering impressive and consistent revenue growth for the past four years. Over this period, the Company has achieved in excess of 100% YOY gross revenue growth and expects to continue that forward momentum in FY 2009. ( To view the interview online visit Fox Business News at (

FOX Business Network (FBN) is a financial news channel delivering real-time information across all platforms that impact both Main Street and Wall Street. FBN is headquartered in New York, the business capital of the world. Launched in October 2007, the Network is available in more than 35 million homes in major markets across the United States. Owned by News Corp., the Network has bureaus in Chicago, Los Angeles, Silicon Valley, Washington, DC and London. (

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 490 people in the U.S. and China. (

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL, Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

    AMDL Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    (Tel :) 206. 310.5323

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Excerpts from DNC Chairman Howard Deans Remarks at the National Baptist Convention
2. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
3. Meth Project Chairman Testifies Before U.S. Senate Finance Committee
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Cardinal Health Names CEO R. Kerry Clark as Chairman; Company Founder Robert D. Walter to Retire After 36 Years
6. Hologic Chairman and CEO to Open NASDAQ Stock Market on October 2, 2007
7. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
8. MGT Chairman and CEO Buys 250,000 MGT shares
9. Sanofi-aventis US Chairman Tim Rothwell Addresses CMSAs Collaborative Practice Summit
10. Hazelden Honors Stephen I. Sadove, Chairman and CEO of Saks Fifth Avenue at its New York Awards Dinner to Benefit Youth and Families
11. Avicena Appoints Dr. Belinda Tsao-Nivaggioli as Chairman of the Board of Directors
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology: